On October 12, 2021, Adamas Pharmaceuticals, Inc. (Adamas) entered into an Agreement and Plan of Merger, dated as of October 10, 202, with Supernus Pharmaceuticals, Inc. (Supernus), and Supernus Reef, Inc. (Purchaser). In connection with the Merger, each of Neil F. McFarlane, David L. Mahoney, Michael F. Bigham, Martha J. Demski, William W. Ericson, John A. MacPhee, Spydion Papapetropoulous and Anna S. Richo resigned as a member of the board of directors of Adamas (the ? Board?) and from all committees of the Board on which such director served, effective as of the Effective Time. Such resignations were not in connection with any disagreement between any of the directors and Adamas. From and after the Effective Time, until their respective successors are duly elected or appointed and qualified in accordance with applicable law, the directors of Purchaser, Bryan Roecklein and Jack Khattar, will be the directors of Adamas pursuant to the terms of the Merger Agreement. In addition, in connection with the Merger, all of Adamas?s current executive officers ceased to be officers of Adamas, effective as of the Effective Time. From and after the Effective Time, until their respective successors are duly elected or appointed and qualified in accordance with applicable law, the officer of Purchaser, Jack Khattar, serving as President, Treasurer and Secretary, will be the sole officer, serving in such respective roles, of Adamas pursuant to the terms of the Merger Agreement.